Introduction and Objective: Heart Failure (HF) in T2D is common and increases mortality. IV Ketone infusion improves EF% ~6% at 3hrs in patients with T2D and HFrEF. Oral ketones (OKE) have shown similar results. Here, we evaluate the effect of chronic OKE administration (7 days) on cardiac efficiency.Methods: 12 subjects with T2D and HFrEF underwent […]
Read MoreCategory: Diabetes
1172-OR: Age-Specific Remote Education Facilitates Successful CGM Use in Older Adults with Diabetes Using Insulin
Introduction and Objective: CGM uptake remains limited in insulin-using older population in spite of data showing its effectiveness in improving glycemic control and lowering hypoglycemia risk. Whether remote education with strategies to overcome age-related barriers can improve adoption of CGM in older population is not known.Methods: In this prospective 6-month intervention study, we enrolled older […]
Read More1165-OR: Predictors of Diabetes Remission and Relapse after Metabolic Bariatric Surgery vs. Medical Lifestyle Intervention: The ARMMS-T2D Study
Introduction and Objective: Metabolic-bariatric surgery (MBS) is highly effective vs. medical-lifestyle intervention (MLI) for ameliorating T2D and promoting remission. Previous models of patient characteristics to predict T2D remission and relapse have used retrospective observational data, often without directly comparing different MBS procedures. The current study identifies clinical characteristics that predict T2D remission and relapse over […]
Read More1197-OR: Visceral Adipose Tissue ICOS hi Treg Cells Mitigates Systemic Metabolic Dysregulation in Diet-Induced Obese Mice
Introduction and Objective: Regulatory T (Treg) cells serve essential roles in immune tolerance and systemic tissue homeostasis remodeling under distinct physiological and pathological conditions. Visceral adipose tissue (VAT) Treg cells constitute a heterogeneous population capable of responding to diverse microenvironmental signals, however, the precise mechanisms by which VAT Treg cells regulate adipose tissue metabolic homeostasis […]
Read More1209-OR: Vagal Innervation, but Not the Hepatic Clock, Is Required for RYGB-Induced Glucose Improvement
Introduction and Objective: The molecular clock regulates energy balance and glucose metabolism. Roux-en-Y gastric bypass (RYGB) modulates these processes, but the underlying neural and hepatic mechanisms remain unclear. Prior findings show that RYGB in CLOCK-deficient mice blunts weight loss, fails to improve glucose homeostasis, and alters hepatic clock-gene rhythms independent of body weight. Because parasympathetic […]
Read More1181-OR: Virtual Behavioral Intervention in Prenatal Care to Limit Gestational Weight Gain and Prevent Gestational Diabetes: A Pragmatic Trial
Introduction and Objective: Excess gestational weight gain (GWG) is common and increases risk for gestational diabetes (GDM), obesity, diabetes. We assessed whether Healthy for Two, a virtual behavioral intervention in prenatal care clinics, vs. usual prenatal care, reduces GWG and GDM among women with pre-pregnancy overweight/obesity using a pragmatic randomized controlled trial design.Methods: Eligibility was […]
Read More1224-OR: Long-Term Association between Depressive Symptoms and Glycemic Control in Youth and Young Adults with Youth-Onset Type 1 Diabetes
Introduction and Objective: To date, limited long-term evidence links depressive symptoms to subsequent glycated hemoglobin (HbA1c) trajectories in youth and young adults (YYAs) with youth-onset type 1 diabetes (T1D). We explored the within- and between-person associations of depressive symptoms and changes therein with HbA1c in YYAs with T1D.Methods: We analyzed longitudinal data from the SEARCH […]
Read More1180-OR: Health Effects of Two Strategies to Enhance Health Care Affordability: Medication-Targeted vs. Broad Out-of-Pocket Cost Reductions
Introduction and Objective: Health care has become unaffordable for many diabetes patients. We examined 3-year health effects of: (1) Preventive Drug List (PDL) benefits that set drug cost sharing to $0, including for insulin, GLP-1 RA, & SGLT2i; (2) switches from high-deductible (HDHP; ≥$1000) to low-deductible health plans (LDHP; ≤$500) that broadly reduce cost sharing […]
Read More1211-OR: ADA Presidents' Select Abstract: Impaired Metabolic Flexibility in Type 1 Diabetes May Be Offset by Greater Physical Activity
Introduction and Objective: Metabolic inflexibility, or an inability to switch between fat and carbohydrate oxidation, has not been thoroughly investigated in T1D despite its close link with skeletal muscle insulin resistance—an established feature of T1D. We investigated whether T1D is characterized by metabolic inflexibility relative to controls without diabetes, and whether physical activity (PA), sedentary […]
Read More1214-OR: Rates of Hepatic Mitochondrial Citrate Synthase Flux, Pyruvate Carboxylase Flux, and Contributions of Glycerol to Endogenous Glucose Production in Type 2 Diabetes
Introduction and Objective: T2D is characterized by increased rates of endogenous glucose production (VEGP) and hepatic insulin resistance, which are strongly linked with MASLD and potential alterations in hepatic mitochondrial function. Because there is limited direct evidence for this in humans we assessed rates of hepatic mitochondrial oxidation [citrate synthase (VCS)] flux and contributions of […]
Read More